$MNPR

Monopar Therapeutics reported a net loss of $3.9 million in Q1 2026, an increase from $2.6 million a year prior, due to higher spending on its drug pipeline, with R&D expenses rising to $3.5 million. The company holds $137.5 million in cash, cash equivalents, and investments as of March 31, 2026, which is expected to fund operations through at least December 31, 2027. Monopar continues to focus on its clinical-stage programs, including ALXN1840 for Wilson disease and radiopharmaceutical programs for advanced cancers, and plans to submit an NDA for ALXN1840 in mid-2026.